Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Current Assets: 2022-2024

Historic Current Assets for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $863.4 million.

  • NewAmsterdam Pharma Co N.V's Current Assets rose 67.25% to $732.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $732.3 million, marking a year-over-year increase of 67.25%. This contributed to the annual value of $863.4 million for FY2024, which is 148.97% up from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Current Assets stood at $863.4 million, which was up 148.97% from $346.8 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's 5-year Current Assets high stood at $863.4 million for FY2024, and its period low was $346.8 million during FY2023.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Current Assets value was $478.0 million (recorded in 2022), while the average stood at $562.7 million.
  • Its Current Assets has fluctuated over the past 5 years, first dropped by 27.45% in 2023, then skyrocketed by 148.97% in 2024.
  • Yearly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Current Assets stood at $478.0 million in 2022, then decreased by 27.45% to $346.8 million in 2023, then spiked by 148.97% to $863.4 million in 2024.